Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle
Marc Kennis, March 1, 2022
Cyclopharm
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!
Stay up-to-date on ASX-listed Life Sciences stocks!
Make sure you subscribe to Stocks Down Under today
No credit card needed and the trial expires automatically.
Blog Categories
Recent Posts
Rule of 72: Here’s how investors can use it to their advantage
Here’s why The Rule of 72 might be useful to consider when investing in Stocks Investing in stocks can be…
Novo Nordisk (CPH: NOVO-B): It’s not all smooth sailing for the US$400bn company behind obesity drug Ozempic
Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year, but Novo Nordisk (CPH:…
Bapcor (ASX:BAP): Its been a horror week with a 3rd profit downgrade in less than a year
This week investors in Bapcor (ASX:BAP) saw a 3rd profit downgrade in less than a year and its CEO-elect walk…